



New York State Medicaid Drug Utilization Review (DUR) Board Meeting
Room 3, Concourse Level, Empire State Plaza, Albany NY
November 6, 2026
9:00am to 4:00pm

The meeting will be available for public viewing as a live and archived webcast
[Department of Health Events and Webcasts](#)

9:00 – 9:15 **Welcome and Introductions**

9:15 – 10:45 **Public Comment Period**

10:45 – 11:00 **Preferred Drug Program (PDP) Review**

The DUR Board will review the therapeutic classes listed below, as they pertain to the PDP ([NYS Public Health Law, Sections 272 and 273](#)), and recommend drugs for preferred or non-preferred status. The review may also include updates to clinical criteria or coverage parameters. The Preferred Drug List (PDL), which includes preferred or non-preferred status and clinical criteria, may be viewed at: [NYRx Preferred Drug List](#). For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information, which is new since the previous review of the therapeutic class and then consider financial information.

1. Anticonvulsants – Other
Previous Review Date: 5/18/2023
2. Antipsychotics – Injectable
Previous Review Date: 9/21/2023
3. Multiple Sclerosis Agents
Previous Review Date: 5/16/2024
4. Antibiotics – Ophthalmic
Previous Review Date: 6/15/2012

11:00 – 12:45 **Drug Utilization Review**

The DUR Board will review the following topics and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

1. Treatment Guidelines for Asthma
2. Xocova (ensitrelvir)



3. Treatment Guidelines for Molluscum Contagiosum

12:45 – 1:30 Lunch / Executive Session

Preferred Drug Program Financial Reviews

1:30 – 1:45 Preferred Drug Program Recommendations

1:45 – 3:55 Drug Utilization Review (continued)

The DUR Board will review the following topics and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

- 4. Treatment Guidelines for Scabies
- 5. Pancreatic Enzymes
- 6. Itivisma (onasemnogene abeparvovec-brve)
- 7. Nereus (tradipitant)

3:55 – 4:00 Final Comments and Adjournment

The agenda timeline is subject to change based on meeting proceedings.

Additional Information

Parties interested in providing public comments during the DUR Board meeting must complete the registration process by October 29, 2026. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes), and the total comment period will not exceed ninety (90) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

Written statements and clinical information can be sent to dur@health.ny.gov. Any studies cited should be referenced, with the primary source of funding included.

Written statements should summarize key points and may not exceed two (2) pages in length. Written statements must be received by October 29, 2026.

Any other clinical information must be received by October 22, 2026.



All information must be sent to the Department of Health (DOH). Interested parties should not contact or send any information directly to DUR Board members.

DUR Board Members may participate by [videoconferencing from a non-public location under extraordinary circumstances](#) if unexpected factor or event precludes physical attendance.
